Literature DB >> 12215718

Selective estrogen receptor modulators.

Henry U Bryant1.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12215718     DOI： 10.1023/a:1020076426727

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN： 1389-9155            Impact factor:   6.514


× No keyword cloud information.
  60 in total

Review 1.  Selective estrogen receptor modulators: tissue selectivity and differential uterine effects.

Authors:  S L Silfen; A V Ciaccia; H U Bryant
Journal:  Climacteric       Date:  1999-12       Impact factor: 3.005

Review 2.  Hormone therapy to prevent disease and prolong life in postmenopausal women.

Authors:  D Grady; S M Rubin; D B Petitti; C S Fox; D Black; B Ettinger; V L Ernster; S R Cummings
Journal:  Ann Intern Med       Date:  1992-12-15       Impact factor: 25.391

3.  LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.

Authors:  M Sato; C H Turner; T Wang; M D Adrian; E Rowley; H U Bryant
Journal:  J Pharmacol Exp Ther       Date:  1998-10       Impact factor: 4.030

4.  Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL).

Authors:  S H Zuckerman; N Bryan
Journal:  Atherosclerosis       Date:  1996-09-27       Impact factor: 5.162

5.  Raloxifene hydrochloride, a selective estrogen receptor modulator: safety assessment of effects on cognitive function and mood in postmenopausal women.

Authors:  T Nickelsen; E G Lufkin; B L Riggs; D A Cox; T H Crook
Journal:  Psychoneuroendocrinology       Date:  1999-01       Impact factor: 4.905

6.  Compartmentalized uterotrophic effects of tamoxifen, toremifene, and estradiol in the ovariectomized Wistar (Han) rat.

Authors:  P Carthew; R E Edwards; B M Nolan; M J Tucker; L L Smith
Journal:  Toxicol Sci       Date:  1999-04       Impact factor: 4.849

7.  Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.

Authors:  C A Frolik; H U Bryant; E C Black; D E Magee; S Chandrasekhar
Journal:  Bone       Date:  1996-06       Impact factor: 4.398

8.  Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

Authors:  B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings
Journal:  JAMA       Date:  1999-08-18       Impact factor: 56.272

9.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

10.  Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model.

Authors:  M M Gottardis; V C Jordan
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701
View more
  5 in total

Review 1.  Role of estrogen treatment in the management of schizophrenia.

Authors:  Jayashri Kulkarni; Emmy Gavrilidis; Roisin Worsley; Emily Hayes
Journal:  CNS Drugs       Date:  2012-07-01       Impact factor: 5.749

2.  Prediction of binding affinity for estrogen receptor alpha modulators using statistical learning approaches.

Authors:  Yonghua Wang; Yan Li; Jun Ding; Yuan Wang; Yaqing Chang
Journal:  Mol Divers       Date:  2008-07-26       Impact factor: 2.943

3.  Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.

Authors:  Matthew J Sikora; Kristine L Cooper; Amir Bahreini; Soumya Luthra; Guoying Wang; Uma R Chandran; Nancy E Davidson; David J Dabbs; Alana L Welm; Steffi Oesterreich
Journal:  Cancer Res       Date:  2014-01-14       Impact factor: 12.701

4.  The role of oestrogen and other hormones in the pathophysiology and treatment of schizophrenia.

Authors:  Emily Hayes; Emorfia Gavrilidis; Jayashri Kulkarni
Journal:  Schizophr Res Treatment       Date:  2012-02-19

5.  Triaryl-substituted Schiff bases are high-affinity subtype-selective ligands for the estrogen receptor.

Authors:  Zong-Quan Liao; Chune Dong; Kathryn E Carlson; Sathish Srinivasan; Jerome C Nwachukwu; Robert W Chesnut; Abhishek Sharma; Kendall W Nettles; John A Katzenellenbogen; Hai-Bing Zhou
Journal:  J Med Chem       Date:  2014-04-07       Impact factor: 7.446
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.